Altimmune Names New Chief Financial Officer
Altimmune, Inc. (Nasdaq: ALT), a pioneering clinical-stage biopharmaceutical company, is making significant strides as it gears up for future growth. The company's Board of Directors recently announced the appointment of Gregory Weaver as the new Chief Financial Officer (CFO). This strategic decision aligns with Altimmune's vision to expand its innovative therapeutic developments.
Introduction to Gregory Weaver
Gregory Weaver brings a wealth of experience to Altimmune. His past roles have equipped him with the skills necessary to lead the company's financial strategies effectively. Hiring seasoned professionals like Mr. Weaver underscores Altimmune’s commitment to fortifying its leadership team as it pushes forward with its ambitious plans.
Equity Awards Under Inducement Grant Plan
To incentivize Mr. Weaver’s new role, the company’s Compensation Committee has approved substantial equity awards under its 2018 Inducement Grant Plan. He has been granted options to purchase 225,000 shares along with 75,000 restricted stock units (RSUs). These awards are designed to align Mr. Weaver's interests with that of the shareholders, ensuring a strong commitment to driving the company’s growth.
Details of the Grant
The inducement awards were approved recently and will vest over time, contingent upon Mr. Weaver's ongoing employment with Altimmune. One-fourth of the options will vest on the anniversary of the Grant Date, with subsequent vesting occurring monthly. This structure incentivizes long-term success and retention, which are essential for any chief executive role.
About Altimmune's Vision
As a company, Altimmune is dedicated to innovation in biopharmaceuticals, particularly in developing peptide-based therapeutics. Their flagship product, pemvidutide, is of particular interest due to its unique mechanism, targeting obesity and MASH (metabolic associated fatty liver disease). Altimmune’s commitment to research and development is evident, and they continue to seek pathways that transform health outcomes through novel therapies.
Markets and Future Prospects
With ongoing clinical trials and a robust pipeline, Altimmune is well-positioned to make significant impacts in the healthcare landscape. Their innovative approaches could lead to groundbreaking treatments in various therapeutic areas, providing hope for many patients dealing with obesity and liver diseases.
Contact Information
In the realm of corporate communication, it’s crucial to maintain transparency. For inquiries regarding investor relations, Vipin Garg, the President and CEO, can be reached at 240-654-1450. Engagement with the community and stakeholders remains a top priority for Altimmune as they advance their clinical missions.
Frequently Asked Questions
What recent position has Gregory Weaver been appointed to at Altimmune?
Gregory Weaver has been appointed as the Chief Financial Officer of Altimmune, Inc.
What equity awards were granted to Gregory Weaver?
Gregory Weaver received options for 225,000 shares and 75,000 restricted stock units as part of his inducement award.
What is Altimmune's focus as a biopharmaceutical company?
Altimmune specializes in developing next-generation peptide-based therapeutics aimed primarily at treating obesity and metabolic diseases.
How do the equity awards vest for Gregory Weaver?
The equity awards will vest over four years, with one-fourth vesting on the first anniversary and the rest vesting monthly thereafter.
Who can I contact for more information about Altimmune?
Vipin Garg, the President and CEO of Altimmune, is available for contact for inquiries related to company information.
